Program
voclosporin
Also written as “LX211”, “Voclosporin” and “LUPKYNIS”.
Its studies are mostly in Lupus Nephritis · Psoriasis · Keratoconjunctivitis Sicca · Uveitis, Posterior · Glomerulosclerosis, Focal Segmental, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aurinia Pharmaceuticals | 171 open or running | phase 4since May 13, 2026 | Oct 25, 2005 | Mar 2, 2029phase 4 · NCT07611214 |
| Lux Biosciences | 50 open or running | phase 3since Nov 27, 2006 | Nov 27, 2006 | none ahead |
| Qilu Pharmaceutical | 11 open or running | phase 3since Mar 20, 2024 | Mar 20, 2024 | Jun 2027phase 3 · NCT06406205 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Oct 25, 2005.
- Apr 25, 2012Phase 3 study in Renal TransplantationAurinia Pharmaceuticals · NCT01586845
- May 14, 2014Phase 2 study in Lupus NephritisAurinia Pharmaceuticals · NCT02141672 · 265 enrolled · United States, Bangladesh, Belarus and more
- Oct 20, 2016Phase 1 study in VolunteersAurinia Pharmaceuticals · NCT02949999 · 40 enrolled · Philippines
- Oct 26, 2016Phase 2 study in Lupus NephritisAurinia Pharmaceuticals · NCT02949973 · 10 enrolled · Malaysia
- Jan 12, 2017Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT03021499 · 358 enrolled · United States, Argentina, Belarus and more
- Jun 14, 2018Phase 2 study in Glomerulosclerosis, Focal SegmentalAurinia Pharmaceuticals · NCT03598036 · 5 enrolled · United States, Dominican Republic
- Jun 25, 2018Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT03597464 · 216 enrolled · United States
- Jul 13, 2018Phase 2 study in Dry Eye SyndromesAurinia Pharmaceuticals · NCT03597139 · 100 enrolled · United States
- Oct 30, 2019Phase 3 study in Dry Eye SyndromesAurinia Pharmaceuticals · NCT04147650 · 508 enrolled · United States
- Feb 7, 2022Phase 1 study in Drug-drug InteractionAurinia Pharmaceuticals · NCT05306379 · 24 enrolled · United States
- Mar 11, 2022Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT05288855 · 9 enrolled · United States, Colombia, Japan and more
- Jun 21, 2023Phase 3 study in Lupus NephritisAurinia Pharmaceuticals · NCT05962788 · 4 enrolled · United States, Colombia, Japan and more
- Mar 20, 2024Qilu Pharmaceutical’s first study: phase 3 study in Lupus NephritisNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06406205 · 270 planned · China
- May 13, 2026Phase 4 study in Lupus NephritisAurinia Pharmaceuticals · NCT07611214 · 150 planned · United States
Ahead
- Jun 2027Primary completion: phase 3 study in Lupus NephritisQilu Pharmaceutical · NCT06406205
- Mar 2, 2029Primary completion: phase 4 study in Lupus NephritisAurinia Pharmaceuticals · NCT07611214
TargetBeta
“Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07611214Lupus Nephritis · United States | 4 | Recruiting | Aurinia Pharmaceuticals | Mar 2, 2029 | 150 |
| NCT06406205Lupus Nephritis · China | 3 | Recruiting | Qilu Pharmaceutical | Jun 2027 | 270 |
| NCT05962788Lupus Nephritis · United States, Colombia, Japan and more | 3 | Terminated | Aurinia Pharmaceuticals | Jul 4, 2025 | 4 |
| NCT05288855Lupus Nephritis · United States, Colombia, Japan and more | 3 | Terminated | Aurinia Pharmaceuticals | Jul 3, 2025 | 9 |
| NCT05306379Drug-drug Interaction · United States | 1 | Completed | Aurinia Pharmaceuticals | Apr 5, 2022 | 24 |
| NCT04147650Dry Eye Syndromes · United States | 3 | Completed | Aurinia Pharmaceuticals | Sep 17, 2020 | 508 |
| NCT03597139Dry Eye Syndromes · United States | 2 | Completed | Aurinia Pharmaceuticals | Nov 9, 2018 | 100 |
| NCT03597464Lupus Nephritis · United States | 3 | Completed | Aurinia Pharmaceuticals | Oct 7, 2021 | 216 |
| NCT03598036Glomerulosclerosis, Focal Segmental · United States, Dominican Republic | 2 | Terminated | Aurinia Pharmaceuticals | May 19, 2020 | 5 |
| NCT03021499Lupus Nephritis · United States, Argentina, Belarus and more | 3 | Completed | Aurinia Pharmaceuticals | Sep 24, 2019 | 358 |
| NCT02949973Lupus Nephritis · Malaysia | 2 | Completed | Aurinia Pharmaceuticals | Dec 2016 | 10 |
| NCT02949999Volunteers · Philippines | 1 | Completed | Aurinia Pharmaceuticals | Dec 2016 | 40 |
| NCT02141672Lupus Nephritis · United States, Bangladesh, Belarus and more | 2 | Completed | Aurinia Pharmaceuticals | Jul 2016 | 265 |
| NCT01586845Renal Transplantation | 3 | Withdrawn | Aurinia Pharmaceuticals | Dec 2015 | 0 |
| NCT01243983Noninfectious Uveitis · United States, Austria, Brazil and more | 3 | Completed | Lux Biosciences | Dec 2012 | 155 |
| NCT00851734Keratoconjunctivitis Sicca · United States | 1 | Completed | Lux Biosciences | Mar 2009 | 35 |
| NCT00408187Psoriasis · Canada, Germany, Poland | 3 | Completed | Aurinia Pharmaceuticals | Dec 2008 | 642 |
| NCT00404885Uveitis, Anterior · United States, Austria, Canada and more | 3 | Completed | Lux Biosciences | Nov 2008 | 108 |
| NCT00404742Uveitis, Posterior · United States, Austria, Canada and more | 3 | Completed | Lux Biosciences | Nov 2008 | 232 |
| NCT00404612Uveitis, Posterior · United States, Austria, Canada and more | 3 | Completed | Lux Biosciences | Nov 2008 | 218 |
| NCT00270634Kidney Diseases · United States, Canada | 2 | Completed | Aurinia Pharmaceuticals | Jul 2009 | 334 |
| NCT00258713Psoriasis · Canada | 3 | Completed | Aurinia Pharmaceuticals | Jul 2006 | 309 |
| NCT00244842Psoriasis · Canada | 3 | Completed | Aurinia Pharmaceuticals | Oct 2005 | 451 |
How it is read
Names in the registry
- “LX211”, 10 entries
- “Voclosporin”, 7 entries
- “voclosporin”, 6 entries
- “LUPKYNIS”, 1 entry
- “Voclosporin(QL1074)”, 1 entry
Conditions, from the studies’ own filings
- Lupus Nephritis, 8 studies
- Psoriasis, 3 studies
- Keratoconjunctivitis Sicca, 2 studies
- Uveitis, Posterior, 2 studies
- Glomerulosclerosis, Focal Segmental, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.